[1]梁 津.针对肺结核不同治疗策略的研究进展[J].大众科技,2022,24(04):90-93.
　Research Progress on Different Treatment Strategies for Pulmonary Tuberculosis[J].Popular Science & Technology,2022,24(04):90-93.
点击复制

针对肺结核不同治疗策略的研究进展()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
24
期数:
2022年04
页码:
90-93
栏目:
医药与卫生
出版日期:
2022-04-20

文章信息/Info

Title:
Research Progress on Different Treatment Strategies for Pulmonary Tuberculosis
作者:
梁 津　
（百色市人民医院，广西 百色 533000）
关键词:
肺结核; 治疗策略; 研究进展
Keywords:
pulmonary tuberculosis treatment strategy research progress
文献标志码:
A
摘要:
肺结核病由结核分枝杆菌引起，属于呼吸道传染病，引发呼吸系统甚至全身的疾病，严重可危及生命。近年来因为耐药、吸烟、社会心理压力大等因素影响，肺结核治疗无法取得更进一步的成效，因此文章从肺结核的主要危险因素入手，对近年来肺结核不同的治疗手段进行综述，以期为后续肺结核的治疗提供临床依据和研究思路。
Abstract:
Pulmonary tuberculosis is caused by mycobacterium tuberculosis, which is a respiratory infectious disease, which causes diseases of the respiratory system and even the whole body. It can be serious and life-threatening. In recent years, due to factors such as drug resistance, smoking, and high social and psychological pressure, tuberculosis treatment has not achieved further results. Therefore, this paper reviews the different treatment methods of pulmonary tuberculosis in recent years from the main risk factors of pulmonary tuberculosis, in order to provide clinical basis and research ideas for the subsequent treatment of pulmonary tuberculosis.

参考文献/References:

[1]　Word Health Organization. Global Tuberculosis Report 2012[R]. Geneva: Word Health Organization, 2012. [2] 李兰娟，任红. 传染病学高级教程[M]. 北京: 人民军医出版社，2015. [3] 靳成娟，杜建，杨怀盛，等. 中国人群肺结核发病危险因素的荟萃分析[J]. 军事医学，2014，38(5): 355-361. [4] Wang E Y, Arrazola R A, Mathema B, et al. The impact of smoking on tuberculosis treatment outcomes: a meta-analysis[J]. International Journal of Tuberculosis and Lung Disease, 2020, 24(2): 170-175. [5] 陈红光，刘民. 糖尿病对肺结核疫情影响的流行病学研究进展[J]. 中国预防医学杂志，2012，13(5): 387-390. [6] 廖庆华，钟球，周琳，等. 艾滋病病毒感染者中肺结核的患病情况分析[J]. 广东医学，2010，31(15): 1926-1927. [7] 李卫彬，马丽萍，李新旭，等. 耐多药肺结核患者治疗结果及其影响因素调查[J]. 临床肺科杂志，2012，17(10): 1831-1834. [8] Islam Q S, Ahmed S M, Islam M A, et al. Beyond drugs: tuberculosis patients in Bangladesh need nutritional support during convalescence[J]. Public Health Action, 2013, 3(2): 136-140. [9] Armijos R X, Weigel M M, Chacon R, et al. Adjunctive micro-nutrient supplementation for pulmonary tuberculosis[J]. Salud Pública de México, 2010, 52: 185-189. [10] Akkerman O W, Ter Beek L, Centis R, et al. Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients[J]. International Journal of Infectious Diseases, 2020, 92: S10-S14. [11] Singh S K, Naaraayan A, Acharya P, et al. Pulmonary rehabilitation in patients with chronic lung impairment from pulmonary tuberculosis[J]. Cureus, 2018, 10(11): e3664. [12] Dewan R K, Pezzella A T. Surgical aspects of pulmonary tuberculosis: an update[J]. Asian Cardiovascular and Thoracic Annals, 2016, 24(8): 835-846. [13] Riskiyev A, Ciobanu A, Hovhannesyan A, et al. Characteristics and treatment outcomes of patients with tuberculosis receiving adjunctive surgery in Uzbekistan[J]. International Journal of Environmental Research and Public Health, 2021, 18(12): 6541. [14] Yablonskii P, Kudriashov G, Vasilev I, et al. Robot-assisted surgery in complex treatment of the pulmonary tuberculosis[J]. Journal of Vascular Surgery, 2017, 3: 18. [15] Marfina G Y, Vladimirov K B, Avetisian A O, et al. Bilateral cavitary multidrug- or extensively drug-resistant tuberculosis: role of surgery[J]. European Journal of Cardio-Thoracic Surgery, 2018, 53(3): 618-624. [16] Han J, Yuan L, Li J, et al. Transbronchial tuberculosis cavity plugging therapy for pulmonary tuberculosis[J]. Journal of International Medical Research, 2021, 49(8): 35889. [17] Zwick E D, Pepperell C S. Tuberculosis sanatorium treatment at the advent of the chemotherapy era[J]. BMC Infectious Diseases, 2020, 20(1): 831. [18] Dobbs T E, Webb R M. Chemotherapy of tuberculosis[J]. Microbiology Spectrum, 2017, 5(2): 40. [19] Liu S S, Wang L Z, Tang S J. Advances in chemotherapy of multidrug-resistant and rifampicin-resistant tuberculosis[J]. Chinese Journal of tuberculosis and respiration, 2020, 43(4): 371-375. [20] 裘星凤. 肺结核治疗研究进展[J]. 世界最新医学信息文摘，2017，17(80): 153. [21] Mori R, Gokan Y, Ishihara T. Public health nurse support at initial community DOTS meetings with non-hospitalized tuberculosis patients--comparison of patients who did and did not complete treatment[J]. Kekkaku, 2013, 88(11): 739-747. [22] Putra A E, Dewi P, Probandari A N, et al. The implementation of comprehensive health education to improve household contacts participation in early detection of tuberculosis[J]. Health Education and Behavior, 2021, 8: 1829. [23] Hu B, Ren G, Zhao L. Effect of health education combined with dietary guidance on nutritional indicator, immune level, and quality of life of patients with pulmonary tuberculosis[J]. Computational and Mathematical Methods in Medicine, 2021, 2021: 9463577. [24] Weissberg D, Weissberg D. Late complications of collapse therapy for pulmonary tuberculosis[J]. Chest, 2001, 120(3): 847-851. [25] Krasnov D V, Skluev S V, Petrova Y K, et al. Modern collapse therapy for pulmonary tuberculosis[J]. Thoracic Surgery Clinics, 2019, 29(1): 47-58. [26] Corbetta L, Tofani A, Montinaro F, et al. Lobar collapse therapy using endobronchial valves as a new complementary approach to treat cavities in multidrug-resistant tuberculosis and difficult-to-treat tuberculosis: a case series[J]. Respiration, 2016, 92(5): 316-328. [27] Bertin F, Labrousse L, Gazaille V, et al. New modality of collapse therapy for pulmonary tuberculosis sequels: tissue expander[J]. Annals of Thoracic Surgery, 2007, 84(3): 1023-1025. [28] 林晶晶，刘旭晖，卢水华. 结核病疫苗的临床试验进展[J]. 中华传染病杂志，2020，38(7): 455-459. [29] 卢锦标，赵爱华，王国治，等. 结核病新疫苗临床研究进展[J]. 中华结核和呼吸杂志，2019(10): 783-790. [30] Saqib M, Khatri R, Singh B, et al. Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis[J]. Tuberculosis, 2016, 101: 164-173. [31] Sharma S K, Katoch K, Sarin R, et al. Efficacy and safety of mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial[J]. Scientific Reports, 2017, 7(1): 3354. [32] King T H, Shanley C A, Guo Z, et al. GI-19007, a novel saccharomyces cerevisiae-based therapeutic vaccine against tuberculosis[J]. Clinical and Vaccine Immunology, 2017, 24(12): e00245-e00247. [33] Okada M, Kita Y, Nakajima T, et al.Novel therapeutic vaccine: granulysin and new DNA vaccine against tuberculosis[J]. Human Vaccines and Immunotherapeutics, 2011, 7: 60-67. [34] Okada M, Kita Y, Hashimoto S, et al.Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis[J]. Human Vaccines and Immunotherapeutics, 2017, 13(2): 298-305.

相似文献/References:

[1]黄莹莹 黄俊逸 何慧敏.广西某医院肺结核患者住院费用及影响因素分析[J].大众科技,2022,24(10):162.
　Analysis of Hospitalization Expenses and Influencing Factors of Pulmonary Tuberculosis Patients in a Hospital in Guangxi[J].Popular Science & Technology,2022,24(04):162.
[2]韦柳迎 文乐敏.糖尿病与肺结核共病的研究进展[J].大众科技,2023,25(8):124.
　Research Progress on Comorbidity of Diabetes and Pulmonary Tuberculosis[J].Popular Science & Technology,2023,25(04):124.

备注/Memo

备注/Memo:
【收稿日期】2022-01-19 【基金项目】广西壮族自治区百色市科学技术局2020年科学研究与技术开发计划《尿激酶联合地塞米松胸腔给药治疗结核性包裹性胸腔积液的临床研究》（百科20202810）。 【作者简介】梁津（1978－），女，百色市人民医院副主任医师，研究方向为西医治疗结核性胸腔积液的防治研究。
更新日期/Last Update: 2022-07-12